Back

Rejuvenation of the Aged Cerebrovascular System via Protein Corona-Guided Fusogenic Liposome Delivery

Shanmugarama, S.; Gronemann, T.; Csik, B.; Patai, R.; Nyul-Toth, A.; Nagy, D.; Hricisak, L.; Nagykaldi, M.; Sanford, M.; Nagaraja, R. Y.; Gulej, R.; Kristof, R.; Kordestan, K. V.; Brunner, E. G.; Negri, S.; Abushukair, H.; Jung, W.; Tarantini, S.; Chandragiri, S. S.; Sirpal, P.; Conley, S.; Mukli, P.; Yabluchanskiy, A.; Mukherjee, P.; Berkamp, S.; Hersch, N.; Kuppusamy, M.; Sachse, C.; Huesgen, P.; Merkel, R.; Kiss, T.; Benyo, Z.; Oh, T. G.; Ungvari, Z.; Csiszar, A.; Csiszar, A.

2026-03-09 animal behavior and cognition
10.64898/2026.03.05.709925 bioRxiv
Show abstract

Brain vascular aging is increasingly recognized as a critical therapeutic target for age-related cognitive decline. Oxidative stress, bioenergetic dysfunction, and molecular damage play central roles in the progression of vascular aging, contributing to cerebrovascular dysfunction and impaired cognitive function. While naturally occurring polyphenols such as resveratrol (RSV) have demonstrated potential in mitigating aging-related pathologies, their poor bioavailability and limited brain targeting efficiency significantly constrain their therapeutic impact. As a result, high doses or advanced drug delivery strategies are necessary to achieve meaningful physiological effects. We introduce a novel nanocarrier system designed to enhance RSV delivery to the cerebral endothelium by leveraging the natural formation of an apolipoprotein E (ApoE)-enriched protein corona around fusogenic liposomes (FL) in vivo. These nanoparticles directly fuse with cytoplasmic cell membranes and thus evade endocytosis. We found that once in the circulation FL spontaneously acquire a protein corona, which is highly enriched in ApoE, a key ligand for brain endothelial low-density lipoprotein receptors (LDLR). Based on this observation, we engineered an ApoE-functionalized protein corona around FL (ApoE-FL) to systematically evaluate whether this mechanism could be exploited for targeted brain delivery. Following optimization and physicochemical characterization, the RSV-loaded liposomes were evaluated in vitro using human cerebral microvascular endothelial cells and in vivo C57BL/6 aged mice to assess their therapeutic potential. Both FL and engineered ApoE-FL liposomal delivery systems exhibited a strong affinity for endothelial cell membranes in vitro. The knockdown of the ApoE receptor, low-density lipoprotein receptor-related protein 1 (LRP1), significantly reduced liposomal docking. Microscopy analysis revealed that both ApoE-FL and non-functionalized FL directly fused with endothelial plasma membranes, thus bypassing intracellular organelles and minimizing lysosomal degradation. This suggests that the naturally formed ApoE corona in vivo may contribute to efficient cerebrovascular targeting, a property successfully replicated by the engineered ApoE corona strategy. In vivo biodistribution and kinetic studies demonstrated that especially ApoE-FL achieved enhanced brain-targeting efficiency, prolonged cerebrovascular retention, and extended targeting distance along the arteriovenous axis. This emphasizes that fusogenic liposomes effectively engage almost the entire microvascular network, including capillaries and post-capillary venules. Functionally, fusogenic liposome-delivered RSV improved blood-brain barrier (BBB) integrity, enhanced neurovascular coupling (NVC) responses, and promoted brain vascularization in aged mice. Single-cell RNA sequencing (scRNA-seq) revealed enhanced endothelial angiogenesis and barrier protective transcriptional profiles in cerebrovascular cells treated with ApoE-FL/RSV, suggesting a molecular basis for the observed vascular benefits. Liposomal RSV delivery achieved near-complete cerebrovascular and cognitive rejuvenation in aged mice applying a 2000-fold lower RSV dose than oral administration used as control sample. Thus, ApoE-FL liposomes exhibited exceptionally high delivery efficiency in deeper brain regions, further expanding their therapeutic potential. These findings underscore the importance of targeted drug delivery in optimizing therapeutic outcomes and establish ApoE-functionalized fusogenic liposomes as a promising strategy for mitigating brain vascular aging and cognitive decline. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=103 SRC="FIGDIR/small/709925v1_ufig1.gif" ALT="Figure 1000"> View larger version (52K): org.highwire.dtl.DTLVardef@f7966dorg.highwire.dtl.DTLVardef@b4ea4corg.highwire.dtl.DTLVardef@18240a9org.highwire.dtl.DTLVardef@634f6a_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Molecular Therapy
71 papers in training set
Top 0.1%
33.5%
2
International Journal of Biological Macromolecules
65 papers in training set
Top 0.1%
14.9%
3
Journal of Controlled Release
39 papers in training set
Top 0.1%
9.3%
50% of probability mass above
4
Nature Communications
4913 papers in training set
Top 42%
3.1%
5
Biomedicine & Pharmacotherapy
43 papers in training set
Top 0.2%
2.6%
6
Advanced Materials
53 papers in training set
Top 0.9%
2.1%
7
Advanced Healthcare Materials
71 papers in training set
Top 0.9%
1.9%
8
Small
70 papers in training set
Top 0.3%
1.9%
9
ACS Nano
99 papers in training set
Top 2%
1.9%
10
Advanced Science
249 papers in training set
Top 9%
1.9%
11
Aging Cell
144 papers in training set
Top 2%
1.8%
12
Journal of the American Chemical Society
199 papers in training set
Top 3%
1.7%
13
eLife
5422 papers in training set
Top 48%
1.2%
14
Journal of Medicinal Chemistry
68 papers in training set
Top 0.8%
1.2%
15
Advanced Functional Materials
41 papers in training set
Top 1%
1.2%
16
Angewandte Chemie International Edition
81 papers in training set
Top 3%
1.0%
17
iScience
1063 papers in training set
Top 26%
0.9%
18
Biomaterials
78 papers in training set
Top 1%
0.8%
19
Advanced Therapeutics
15 papers in training set
Top 0.4%
0.8%
20
Alzheimer's & Dementia
143 papers in training set
Top 3%
0.8%
21
Chemical Science
71 papers in training set
Top 2%
0.7%
22
Vaccines
196 papers in training set
Top 3%
0.7%
23
Communications Chemistry
39 papers in training set
Top 1%
0.7%
24
Nanoscale Advances
13 papers in training set
Top 0.7%
0.5%
25
Aging
69 papers in training set
Top 4%
0.5%
26
Molecular Therapy Nucleic Acids
32 papers in training set
Top 1%
0.5%